Description
This page contains brief details about the drug granisetron, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Granisetron is an antiemetic drug that belongs to the class 5-HT 3 receptor antagonists and is effective against nausea and vomiting. It was approved by the FDA on 25 July 1
Mechanism of Action of Granisetron
Granisetron is a potent, selective antagonist of 5-HT3 receptors. The antiemetic (effective against vomiting and nausea) activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors, in turn, blocks the substance serotonin, a natural substance in the body that causes nausea and vomiting.
Uses of Granisetron
Granisetron is indicated to prevent nausea and vomiting associated with initial and repeated courses of emetogenic (a substance that causes vomiting) chemotherapy and radiation therapy. It is also used to treat and prevent nausea and vomiting in adults that may occur after surgery.
Granisetron Dosage available
Granisetron is a prescription generic drug available as an injectable solution, extended-release subcutaneous injection, transdermal patch, tablet, and oral solution. The oral dose is given 1 hour before chemotherapy, followed by 12 hours after chemotherapy to prevent chemotherapy-induced nausea and vomiting. The recommended injection dose is 10 mcg/kg intravenously 30 minutes before chemotherapy. Your doctor will decide the dose, frequency, and dosage based on the severity of the condition. To prevent radiation-induced nausea and vomiting, the recommended dose is given orally 1 hour before radiation therapy. To prevent postoperative nausea and vomiting, the recommended dose is given intravenously before induction of anesthesia. To treat postoperative nausea and vomiting, the recommended dose is given intravenously.
